André Archambault

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

S. Targan, M. Kamm, C. Hawkey, 2001, Gastroenterology.

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

J. Rochon, B. Feagan, R. Fedorak, 1994, Gastroenterology.

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.

S. Hanauer, W. Sandborn, B. Yacyshyn, 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.

A. Laupacis, J. Rochon, B. Feagan, 1994, The New England journal of medicine.

Communication of Verbal Information by Community Pharmacists

A. Contandriopoulos, C. Laurier, Andre Archambault, 1989, DICP : the annals of pharmacotherapy.

Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.

D. Graham, J. Weiss, B. Fleshler, 1984, The New England journal of medicine.